ARA-290

ARA-290 (Cibinetide)



ARA-290 (Cibinetide) is a synthetic peptide derived from erythropoietin (EPO) that selectively activates the Innate Repair Receptor (IRR) without stimulating red blood cell production. It is being investigated for its potential tissue-protective, anti-inflammatory, neuroprotective, and regenerative properties.



Potential Benefits



Nerve Health



* Supports peripheral nerve repair

* May reduce neuropathic discomfort

* Promotes healthy nerve function

* Investigated for small fiber neuropathy



Tissue Repair



* Supports the body’s natural healing response

* Promotes tissue regeneration

* May accelerate recovery after injury

* Supports cellular repair mechanisms



Anti-Inflammatory Support



* Helps regulate inflammatory responses

* May reduce chronic inflammation

* Supports healthy immune signaling

* Protects tissues from inflammatory damage



Neuroprotection



* Supports healthy neuronal function

* May protect nerve cells from oxidative stress

* Investigated for neurodegenerative conditions

* Promotes nervous system resilience



Metabolic & Organ Support



* Investigated for kidney protection

* May support cardiovascular health

* Supports healthy vascular function

* Promotes overall cellular resilience



Mechanism of Action



ARA-290 works by:



* Selectively activating the Innate Repair Receptor (IRR)

* Supporting tissue repair and regeneration

* Reducing inflammatory signaling

* Protecting cells from oxidative stress

* Promoting healing without increasing red blood cell production



Suggested Administration



ARA-290 is generally administered by subcutaneous (SC) injection in research settings. There is no FDA-approved dosing regimen for general clinical use.



Storage



* Store lyophilized peptide refrigerated (2–8°C / 36–46°F)

* After reconstitution, refrigerate

* Protect from light

* Avoid repeated freeze-thaw cycles



Possible Side Effects



Available clinical studies suggest ARA-290 is generally well tolerated. Reported or potential side effects include:



* Mild injection site irritation

* Headache

* Nausea

* Temporary fatigue

* Dizziness (uncommon)



Research Areas



* Small fiber neuropathy

* Diabetic neuropathy

* Chronic pain

* Tissue repair and regeneration

* Kidney disease

* Cardiovascular protection

* Inflammatory disorders



Notes



* ARA-290 (Cibinetide) is an investigational peptide and is not FDA-approved for routine clinical use.

* It does not stimulate red blood cell production like erythropoietin (EPO).

* Current evidence comes from preclinical research and early-stage clinical trials. Additional studies are needed to establish its long-term safety and effectiveness.